MiNK Therapeutics, Inc. — Q3 2021 Form 10-Q
Reporting period: Three and nine months ended September 30, 2021. MiNK is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies. It reported no product revenue and remains dependent on external financing while advancing early-stage programs.
Financial results and liquidity
| Metric | Q3 2021 / September 30, 2021 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $3.3 million for Q3; $10.0 million for nine months | $2.5 million for Q3 2020; $8.7 million for nine months 2020 |
| General and administrative expense | $0.8 million for Q3; $2.3 million for nine months | $0.5 million for Q3 2020; $1.6 million for nine months 2020 |
| Net loss | $14.3 million for Q3; $24.4 million for nine months | $6.0 million for Q3 2020; $14.7 million for nine months 2020 |
| Net loss per share | $0.59 for Q3; $1.01 for nine months | $0.25 for Q3 2020; $0.61 for nine months 2020 |
| Cash and cash equivalents | $0.8 million | $2.7 million at December 31, 2020 |
| Operating cash use | $11.1 million for nine months | $6.6 million for nine months 2020 |
| Convertible affiliated note | $65.4 million fair value, classified current; $45.5 million principal | $43.8 million fair value, classified non-current at December 31, 2020 |
Margins are not meaningful because the company reported no revenue. The increased loss included a $9.7 million nine-month noncash fair-value loss on the Agenus convertible note, compared with $2.8 million in the prior-year period. Interest expense was $2.4 million versus $1.8 million. The quarter also included a $0.36 million gain from forgiveness of a Small Business Administration Paycheck Protection Program loan.
At September 30, current assets were $3.4 million against current liabilities of $80.6 million; total assets were $4.1 million and stockholders’ deficit was $76.5 million. The note automatically converted into 5,451,958 common shares upon the October 2021 IPO. The company subsequently received approximately $42.8 million in net IPO proceeds and said cash plus those proceeds would fund requirements for more than one year from issuance of the statements. The IPO and note conversion are subsequent events, not September 30 balance-sheet amounts.
Material changes and business developments
- For the first nine months, R&D expense rose 15% and G&A expense rose 43% year over year; net loss increased by $9.7 million. Management attributed higher spending mainly to preclinical and clinical activity, personnel and Agenus service allocations; higher G&A also reflected increased stock-based compensation.
- The Agenus note’s principal balance increased from $36.1 million at year-end 2020 to $45.5 million at September 30, 2021. It carried 8% interest, accrued without current payment, and converted after quarter-end at 80% of the IPO share price.
- In September, MiNK entered new Agenus agreements covering administrative services and intellectual property. Agenus provides services on a cost-plus basis at 105% of its costs. MiNK also received assigned and licensed iNKT-related rights, subject to agreement terms.
- The company discontinued research efforts on a Belgium Walloon Region program in 2020. A $5.4 million repayable advance remained recorded as a liability; repayment obligations were unresolved.
Outlook, risks, and contingencies
- No formal financial guidance was provided. Management expects continued operating losses and negative cash flows, and states development costs and timing of future cash inflows cannot be reliably estimated. It may seek collaborations, licensing or partnering, asset sales, debt, or equity funding.
- AGENT-797 was MiNK’s lead clinical candidate. Management expected multiple-myeloma Phase 1 top-line data in Q4 2021; preliminary solid-tumor trial readouts in the first half of 2022; and GvHD data in the second half of 2022. The company also described plans to expand its ARDS trial to include influenza and other viral causes. These are management expectations, not guarantees.
- The filing cites company-reported Phase 1 COVID-19 ARDS data with a 77% survival rate in older, mechanically ventilated patients. The result is early-stage and should not be treated as evidence of established efficacy; the filing discusses uncertainty in interim data and clinical outcomes.
- Key risks include clinical, regulatory, manufacturing and patient-enrollment uncertainty; reliance on third parties and Agenus; the need for additional capital; potential dilution; competition; and intellectual-property and data-security risks. MiNK noted that fewer COVID-19 ARDS hospitalizations slowed trial enrollment.
- Agenus retained majority ownership and may exert significant influence. The company also disclosed possible conflicts arising from shared directors and officers and continuing reliance on Agenus facilities and services.
- The filing states no material legal proceedings were pending. It describes potential litigation generally and identifies no clear resolution of the Walloon Region’s repayment claim.
Most important facts for investors to verify
- Whether the stated clinical milestones and reported AGENT-797 results were achieved, and the status, size, design and follow-up of each trial.
- Post-IPO cash, actual cash burn and runway, including whether the stated more-than-one-year liquidity assessment remains valid.
- The final amount, timing and any conditions of repayment for the $5.4 million Walloon Region advance.
- The effect of the note conversion and IPO on share count, dilution, ownership and related-party arrangements with Agenus.
- The assumptions behind the convertible note’s fair-value measurement and the accounting effects of its subsequent conversion.